On Jul. 22, 2020, RedHill Biopharma announced that it had submitted a Clinical Trial Application (CTA) with the Mexican Federal Committee for the Protection against Sanitary Risks and initiated CTA submission with the Brazilian Health Regulatory Agency for the Phase 2/3 clinical study evaluating opaganib (Yeliva, ABC294640)1 in patients hospitalized with severe SARS-CoV-2 infection (the cause of COVID-19) and pneumonia.